A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Phase of Trial: Phase I/II
Latest Information Update: 25 Mar 2018
Price : $35 *
At a glance
- Drugs Binimetinib (Primary) ; Imatinib
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2021.
- 10 Oct 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2021.
- 02 Jun 2015 Interim results for the phase I portion presented at the 51st Annual Meeting of the American Society of Clinical Oncology.